2017 Annual Meeting
SC36-The Updated WHO Classification of Myeloid Neoplasms: A Practical Approach to Genetically-Defined and Not-So-Well Defined Entities
March 8 2017, 8:00am to 12:00pm
SC 36 The Updated WHO Classification of Myeloid Neoplasms: A Practical Approach to Genetically-Defined and Not-So-Well Defined Entities
Session Credits: 3 CME and 3 SAMs
Faculty: Attilio Orazi, MD, FRCPath, Weill Cornell Medical College, New York, NY, Daniel A. Arber, MD, University of Chicago, Chicago, IL and Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA
The World Health Organization (WHO) is implementing a revised Classification of Tumours of the Haematopoietic and Lymphoid Tissues, scheduled for release in 2017. For the group of the myeloid neoplasms, several modifications in terminologies and diagnostic guidelines have been included in the updated classification. The knowledge of this new classification scheme and how it should be applied in a clinical diagnostic settings is of great importance. The careful integration of recent molecular discoveries provides unique challenges for hematopathologists diagnosing these neoplasms. Despite recent advances, careful morphologic evaluation and clinical correlation remain essential components of well-integrated evidence-based diagnosis, which is a key factor in achieving optimal clinical management of these neoplasms. This course will enhance the diagnostic skills of the pathologists, especially hematopathologists, who often deal with these challenging neoplasms. The course, directed by three of the authors of the upcoming “blue book”, will comprehensively educate pathologists on the new classification. It will use clinical cases to explain in a practical manner the rationale of the changes made in various diagnostic entities. The participant should expect to benefit by achieving a better uniformity of interpretation and enhanced and up-to-date diagnostic skills.